New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Abdelkarim, Mohamed ^a,b   Guenin, Erwann ^a   Sainte Catherine, Odile ^a   Vintonenko, Nadejda ^a,b   Peyri, Nicole ^b   Perret, Gerard Yves ^a   Crepin, Michel ^b   Khatib, Abdel Majid ^b   Lecouvey, Marc ^a   Di Benedetto, Mélanie ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

[2 (3 BROMOPHENYL) 1 HYDROXY 1 [HYDROXY (4 METHOXYPHENOXY)PHOSPHORYL]ETHYL] PHOSPHONIC ACID 4 METHOXYPHENYL ESTER; [2 (3 BROMOPHENYL) 1 HYDROXY 1 PHOSPHONOETHYL]PHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BP 7033BR; BP 7033BR ALK; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; ESTERIFICATION; FEMALE; HUMAN; HYDROPHOBICITY; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DIPHOSPHONATES; ESTERIFICATION; FEMALE; HUMANS; HYDROPHOBICITY; NEOPLASM METASTASIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61849100970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004685     Document Type: Article

References (34)

1. Clezardin P, Ebetino FH, Fournier P (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65: 4971-4974.
2. Clezardin P, Fournier P, Boissier S, Peyruchaud O (2003) In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10: 173-180.
3. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, et al. (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13: 7-26.
4. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97: 840-847.
5. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32): 2643-2658.
6. Van den Wyngaert T, Huizing MT, Vermoken JB (2006) Bisphosphonates and osteonecrosis of the jaw: cause and effect of a post hoc fallacy? Ann Oncol 17: 1197-1204.
7. Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, et al. (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 64: 198-207.
8. Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12: 6222s-6230s.
9. Stresing V, Daubine F, Benzaid I, Monkkonen H, Clezardin P (2007) Bisphosphonates in cancer therapy. Cancer Lett 257 (1): 16-35.
10. Ezra A, Golomb G (2000) Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev 42: 175-195.
11. Migianu E, Monteil M, Even P, Lecouvey M (2005) Novel approach to nucleoside-5′-(1-hydroxymethylene-1, 1-bisphosphonates): synthesis of new AZT analogues. Nucleosides Nucleotides Nucleic Acids 24: 121-133.
12. Ledoux D, Hamma-Kourbali Y, Di Benedetto M, Foucault-Bertaud A, Oudar O, et al. (2006) A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice. Anti-Cancer Drugs 17: 479-485.
13. Guenin E, Ledoux D, Oudar O, Lecouvey M, Kraemer M (2005) Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro. Anticancer Res 25: 1139-1145.
14. Mao J, Mukherjee S, Zhang Y, Cao R, Sanders JM, et al. (2006) Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. J Am Chem Soc 128: 14485-14497.
15. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7(4): 444-454.
16. Journe F, Chaboteaux C, Dumon J-C, Leclercq, Laurent G, Body J-J (2004) Steroid-free medium discloses oestrogenic effects of bisphosphonate clodronate on breast cancer cells. Brit J Cancer 91: 1703-1710.
17. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8): 1459-1468.
18. Monkkonen H, Kuokkanen J, Holen I, Evans A, Lefley DV, et al. (2008) Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19(4): 391-399.
19. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15(11): 2211-2221.
20. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ (1998) Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 7(4): 581-599.
21. Hamma-Kourbali Y, Di Benedetto M, Ledoux D, Oudar O, Leroux Y, et al. (2003) A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis. Biochem Biophys Res Comm 310: 816-882.
22. Kavanagh KL, Dunford JE, Bunkoczi G, Russell RG, Oppermann U (2006) The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 281(31): 22004-22012.
23. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nature Med 12(8): 895-904.
24. Wang W, Wyckoff JB, Frohlich VC, Oleynikov Y, Hüttelmaier S, et al. (2002) Single cell behaviour in metastatic primary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res 62: 6278-6288.
25. Winter M, Holen I, Coleman RZ (2008) Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat rev 34(5): 453-75.
26. Sebbah-Louriki M, Colombo BM, el Manouni D, Martin A, Salzmann JL, et al. (2002) A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects. Anticancer Res 22(6C): 3925-3931.
27. Higara T, Williams PJ, Mundy GR, Yoneda T (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61(11): 4418-4424.
28. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, et al. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55(16): 3551-3557.
29. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, et al. (2006) Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12(9): 2862-2868.
30. Alberts S, Hallum AV, Stratton-Custis M, Garcia D J, Gleason-Guzman M, et al. (2001) Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res 7: 1246-1250.
31. Lecouvey M, Mallard I, Bailly T, Burgada R, Leroux Y (2001) A mild and efficient one-pot synthesis of 1-hydroxymethylene-1,1-Bisphosphonic acids. Preparation of a new tripod ligands. Tetrahedron lett 42: 8475-8478.
32. Monteil M, Guenin E, Migianu E, Lutomski D, Lecouvey M (2005) Bisphosphonate prodrugs: Synthesis of new aromatic and aliphatic 1-hydroxy-1,1-bisphosphonate partial esters. Tetrahedron lett 61: 7528-7537.
33. Tetko IV, Jaroszewicz I, Platts JA, Kuduk-Jaworska J (2008) Calculation of lipophilicity for Pt(II) complexes: experimental comparison of several methods. J Inorg Biochem 102: 1424-1437.
34. Mosmann T (1983) Rapid colorimetric assay for cell growth ans survival:Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.